Skye Buys Redx With $125M Financing
Skye Bioscience agreed to acquire Redx Pharma, with $125M in new financing supporting the deal.
A biotech acquisition is combining pipeline expansion with fresh financing.
What happened
Skye Bioscience agreed to acquire Redx Pharma, a UK biotech focused on fibrotic diseases. The deal includes $125M of new financing from Abingworth, British Business Bank, NEXTBio Capital and 5AM Ventures.
The transaction brings together an acquisition and a capital raise to support the combined company’s clinical strategy.
Why it matters
This is a biotech consolidation signal. Smaller public and private biotechs are still using M&A plus new financing to build more focused pipelines in specialist disease areas.
The structure matters because biotech companies often need both assets and capital to move through expensive clinical development.
The bigger picture
Biotech has been through a difficult financing cycle, but targeted deals are still happening where investors see a clearer clinical thesis. Fibrotic disease remains a serious unmet-need area, and acquisition-led pipeline building can be a way to concentrate resources around specific programmes.